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Abstract
Background Adverse drug reactions are a recognised
cause of hospital admissions. A small group of medicines
carry a higher risk of adverse outcomes and are more fre-
quently involved in hospital admissions than other medi-
cines. These ‘high-risk medicines’ have been identified in
previous research. However, it is less clear how to reduce
the risks associated with these known high-risk medicines,
or which high-risk medicines should be prioritised when
implementing risk reduction interventions. Previous
research has questioned the efficacy of pharmacist-led
medication reviews in reducing hospital admissions and
drug-related morbidity and mortality.
Objectives In this study, we aimed to identify high-risk
medicines through medication review to reduce iatrogenic
disease; to determine a short list of high-risk medicines to
target in medication reviews to achieve the greatest impact
on reducing iatrogenic disease and patient harm; and to
determine whether pharmacist-conducted medication
reviews of high-risk medicines are safe and effective.
Methods A prospective cohort study was undertaken in
16 general practices in one Scottish health board. All
patients prescribed a high-risk medicine were identified
and received a medication review from a pharmacist (3643
patients from a total population of 38,399). The pharmacist
decided whether it was appropriate to continue the high-
risk medicine, or if the medicine should be stopped or
amended. The pharmacist made recommendations to the
patient’s general practitioner (GP) for medicines to be
stopped or amended, which the GP could choose to accept
or not. Patient outcomes for all of the pharmacist’s rec-
ommendations were identified 1 year later to determine the
effectiveness of the recommendations.
Results High-risk medicines were prescribed to 3643
patients from a total population of 38,399 patients. The
pharmacist made 440 recommendations for GPs to stop or
amend high-risk medicines. GPs accepted 214 recom-
mendations and rejected 226, giving an acceptance rate of
49 %. The 440 recommendations were then followed up
1 year later. The risk of having an adverse outcome was
significantly reduced when the pharmacist’s recommen-
dation to stop or amend a high-risk medicine was fol-
lowed compared with rejecting the pharmacist’s
recommendation and continuing the high-risk medicine
unchanged (p\ 0.001). A total of 22 adverse outcomes
occurred when the pharmacist’s advice was rejected. Of
these, 21 would have been prevented if the pharmacist’s
recommendation had been followed and three resulted in
hospital admission.
Conclusions This study demonstrated that medication
reviews for high-risk medicines are safe and effective,
with results achieved within 1 year of the initial
review. It identified six high-risk medicines that could
form the basis of targeted medication reviews in order
to reduce iatrogenic disease. It also demonstrated that




1 National Health Service Highland, Larachan House, 9
Dochcarty Road, Dingwall IV15 9UG, UK
2 National Health Service Highland, Naver Teleservice Centre,
Bettyhill, Sutherland KW14 7SS, UK
Drugs - Real World Outcomes (2015) 2:261–271
DOI 10.1007/s40801-015-0031-8
Key Points
Targeted medication reviews of six key high-risk
medicines can reduce iatrogenic disease in as little as
1 year.
Pharmacists can deliver medication reviews safely
and effectively.
1 Introduction
Around 5 % of all hospital admissions are caused by
adverse drug reactions, with a higher rate of up to 17 % in
frail populations [1–4].
This is important in the context of polypharmacy. It is
widely recognised that medication is the most common
form of medical intervention: 80 % of people aged over
75 years take a prescription medicine [5]. Furthermore,
there is an increasing burden of people with multiple co-
morbidities. Current disease management guidelines focus
on treating each disease in isolation, which results in sig-
nificant levels of polypharmacy, and such guidelines do not
take into account the holistic management of a patient [6].
Since work began on this study, a national polypharmacy
guideline was published in Scotland to try to tackle inap-
propriate polypharmacy [7].
A small group of medicines is frequently implicated in
hospital admissions, termed in this study as ‘high-risk
medicines’. Medicines can have a higher risk of an adverse
event because of three types of risk factor: the effect of the
medicine itself, the result of combining two or more
medicines, or patient-specific risk factors. Such high-risk
medicines have been described by previous research [8]
and a recent systematic literature review listed 46 tools to
identify high-risk medicines and inappropriate prescribing
[9]. In this study, the high-risk medicines were defined by
the National Health Service (NHS) Highland Polyphar-
macy Guideline [10], which was a precursor to the Scottish
Polypharmacy Guidance [7].
Therefore, this study was not about identifying the high-
risk medicines that can cause adverse events. Instead, we
hypothesised that by identifying all patients being pre-
scribed known high-risk medicines and taking actions to
minimise risk, the rate of iatrogenic disease associated with
these medicines could be reduced.
The aim of our study was to identify a short list of high-
risk medicines for which there is the greatest benefit to
patients of targeted medication review. This short list could
be used as a component of regular medication reviews in
primary care by either pharmacists or GPs, with the aim of
reducing iatrogenic disease and patient harm.
The value of medication review, including using a
pharmacist to provide reviews, has been previously
described [11, 12]. However, two large systematic reviews
of 38 [13] and 32 [14] trials have found there is, at best,
only weak evidence that pharmacist-led medication
reviews are effective in reducing hospital admissions or
drug-related morbidity and mortality. One of these reviews
[13] calls for more trials of primary care-based pharmacist-
led interventions to decide whether or not this intervention
is effective.
We believe our study is the first to take a systematic
approach to identify all patients in a defined geographical
area who take a high-risk medicine, take appropriate action
and then follow up 1 year later.
2 Method
2.1 Setting
NHS Highland is the largest geographical health board in
the United Kingdom, covering approximately 32,500 km2
(12,500 miles2) and representing 41 % of the land mass of
Scotland. The population, however, is only around 320,000
(6 % of the Scottish population). This research was con-
ducted within the North area of NHS Highland; all 17
primary care medical practices were invited to participate.
2.2 Study Design
The study was a prospective cohort study.
2.3 High-Risk Medicines
High-risk medicines and high-risk medicine combinations
were identified from the NHS Highland Polypharmacy
Guidance [10] and developed with reference to additional
information on anticholinergic drugs [15] and the STOPP/
START tool (Screening Tool of Older Persons’ Prescrip-
tions/Screening Tool to Alert doctors to Right Treatment)
[16]. The medicines and medicine combinations searched
for in the study are listed in Table 1.
2.4 Patient Identification
All patients prescribed one or more of the high-risk
medicines on a repeat prescription were identified via a
search of the practices’ computerised prescribing system.
There were no exclusions.
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Table 1 High-risk medicines and medicine combinations included in this study
High-risk category Medicine details
NSAID plus Angiotensin conversing enzyme inhibitor/angiotensin II receptor antagonist and diuretic
eGFR below 60 mL/min
Heart failure
Warfarin







Heart failure plus Glitazone
NSAID
Tricyclic antidepressant
Aged over 60 years and taking Benzodiazepines/hypnotics
Tricyclic antidepressants
Antipsychotics (including prochlorperazine for nausea/vertigo)
Sedating antihistamines
Anticholinergics (see list below)
Antihypertensive plus diuretic
Digoxin


































eGFR estimated glomerular filtration rate, NSAID non-steroidal anti-inflammatory drug, PPI proton pump inhibitor
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2.5 Medicines Review
The medicines review protocol was developed by an expert
team of two primary care pharmacists, two hospital phar-
macists and a consultant physician specialising in care of
the elderly. The reviews were undertaken at the medical
practices by a senior clinical pharmacist between June
2012 and February 2013. The review process is illustrated
in Fig. 1.
All patients for whom a recommendation to alter a
prescription was made were followed up 12 months later.
This involved review of the medical notes by a team of
primary care clinical pharmacists using a standard phar-
maceutical resource [17] to describe and categorise the
outcomes as one of the following:
• Medicine stopped: no adverse consequences; adverse
consequence; original medicine restarted; or alternative
medicine started.
• Medicine amended: no adverse consequences; adverse
consequence; original medicine restarted; or alternative
medicine started.
For all patients where the GP continued the medicine
unchanged despite the pharmacist recommendation, the
medical notes were reviewed to determine any untoward
medicine-related effects including adverse drug reactions,
hospital admissions or other medicine-related morbidity.
Preventability of these effects was determined by reference
to standard reference sources by two independent pharma-
cists [17]. These were categorised as one of the following:
• Medicine continued: no adverse consequences; adverse
consequences; or later actions taken.
2.6 Data Analysis
Data were recorded in a spreadsheet designed for the
project by a team of primary care clinical pharmacists.
Data were then analysed by the two authors working
independently from each other and were cross-checked
before recording the final outcomes.
A statistical analysis was undertaken using Fisher’s
exact test to assess whether following the pharmacist’s
recommendations altered the risk of having an adverse
outcome related to a high-risk medicine. Fisher’s exact test
was calculated using a 2 9 2 contingency table using
GraphPad software [18]. Potential confounding factors in
the decision to accept or reject the pharmacist’s recom-
mendations were not controlled for.
2.7 Governance
This study was deemed service evaluation and hence was
exempt from NHS ethical and research and development
reviews.
3 Results
Sixteen of the seventeen primary care medical practices
agreed to take part, with the one remaining practice
expressing interest but was unable to participate due to a
shortage of physician resources. The demographics of the
16 practices are provided in Table 2. The overall trend is of
an older population (22 % aged over 65 years) living either
in very remote small towns or very remote and rural small
settlements.
Of the combined practice populations of 38,399 patients,
9.5 % (3643) were prescribed one or more high-risk
medicines. For the majority of these patients (87.4 %,
3184), the pharmacist deemed the medicine and monitoring
to be appropriate, and that the benefits of continuing
treatment outweighed the risks.
Recommendations to amend the prescription or depre-
scribe a high-risk medicine were made 459 times. Some of
these recommendations involved one patient who took
more than one high-risk medicine, therefore the evaluation
is of 459 recommendations rather than 459 patients (21
patients had two recommendations, seven patients had
Pharmacist reviewed medical notes to determine original 
indication(s) and continuing need 
Pharmacist considered appropriateness for individual patients in 
terms of: 
1. co-morbidities, other medicines 
2. adverse events, safety 
3. patient factors such as reported adherence, social functioning etc 
4. risk:benefit ratio 
Pharmacist submitted recommendations to patient’s GP using a 
standardised template (see Appendix 1): 
1. continue prescription 
2. amend prescription, monitoring 
3. stop prescription (deprescribe)  
GP reviewed recommendations and documented on standard form: 
1. accept recommendation (stop or amend prescription)  
2. reject recommendation (continue prescription unchanged) 
Any change implemented by GP or pharmacist: prescription 
changed and patient contacted to discuss changes  
Pharmacist identified patients receiving high risk medicine(s) by 
search of GP computer system 
Forms returned to pharmacist for evaluation 
Fig. 1 Process for medicines review
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three recommendations, the remainder had one recom-
mendation). Of the 459 recommendations, 19 were for
patients who were lost to follow up. Therefore, the final
number of recommendations included in the study was 440.
Of these 440 recommendations, 413 (94 %) were for
patients aged over 60 years.
Of the 440 recommendations made, GPs accepted 214
recommendations and rejected 226, giving an average
acceptance rate of 49 % (range 20–80 %, see Table 3). If
the three GP practices with low acceptance rates are
excluded, the acceptance rate is 61 %. Reasons for rejecting
recommendations were varied: in some cases it was due to
patient-specific clinical factors such as a patient’s reluc-
tance to withdraw a hypnotic or patient willingness to
accept the risks associated with a particular medicine
combination. A pattern of lower acceptance rate (seen at
three GP practices) may have been due to a lack of GP
engagement with the study.
The 440 recommendations were then followed up 1 year
later. No patients were lost to follow up. The results are
summarised in Table 4. A detailed breakdown of the 440
recommendations is shown in Table 5.
In 22 (10 %) of the 226 rejected recommendations, an
adverse event occurred. The 22 events are shown in
Table 6. All but one of the events was the specific event
that the pharmacist’s recommendation related to. Three
events resulted in hospital admission and 19 resulted in an
additional GP consultation.
In the group in which the pharmacist’s recommendation
was rejected and the original medicine was continued, later
action was taken by the GP in 24 % of cases. In 95 % of
these cases, the action was the same as had been recom-
mended by the pharmacist and was taken to reduce the risk
of an adverse event. The most frequent actions were to stop
a non-steroidal anti-inflammatory drug (NSAID) or hyp-
notic, to reduce the dose of a hypnotic and to change to a
safer NSAID.
In the group in which the pharmacist’s recommendation
was accepted and the original medicine was stopped or
amended, the original medicine had to be re-started in
16 % of cases. These medicines are listed in Table 7. The
reason for medicines being re-started was identified from
patients’ medical records: a reason was stated in 30 out of
35 cases. For all 30, the original medicine was re-started at
the patient’s request due to a loss of symptomatic control
without the medicine. Of these, 29 % were NSAIDs for
pain; 29 % were hypnotics for insomnia and 23 % were
tricyclic antidepressants frequently used in low doses at
Table 2 Demographics of the 16 primary care medical practices
Practice Practice population Patients aged over 65 years (%) Urban/rural classificationa Average deprivation quintileb
1 6030 18.31 5 3
2 5721 22.76 5 3
3 512 30.27 8 2
4 2855 22.87 8 3
5 1248 23.40 8 1
6 7623 18.05 5 2
7 2275 18.46 5 2
8 805 28.45 8 3
9 2479 27.35 8 4
10 304 25.33 8 2
11 2035 25.50 8 3
12 1209 27.63 8 3
13 636 23.90 8 3
14 532 24.62 8 3
15 2490 29.72 8 2
16 1645 26.75 8 3
This table is based on Community Health Index data from 2012 and 2013, available from NHS Information Services Division Scotland
a Urban/rural classification: Urban 1: large urban settlements of over 125,000 people. Urban 2: other urban settlements of 10,000–125,000
people. Urban 3: accessible small towns (settlements of 3000–10,000 people, within 30 min drive of a settlement of 10,000 or more). Urban 4:
remote small towns (settlements of 3000–10,000 people, within 30–60 min drive of a settlement of 10,000 or more). Urban 5: very remote small
towns (settlements of 3000–10,000 people, more than 60 min drive of a settlement of 10,000 or more). Urban 6: accessible rural (settlements of
less than 3000 people within 30 min drive of a settlement of 10,000 or more). Urban 7: remote rural (settlements of less than 3000 people, within
30–60 min drive of a settlement of 10,000 or more). Urban 8: very remote rural (settlements of less than 3000 people, more than 60 min drive of a
settlement of 10,000 or more)
b Average quintile of deprivation from 1 = most deprived to 5 = least deprived
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night only for anxiety/insomnia/pain symptoms. In no case
was the need to re-start a medicine due to an adverse event.
Although a loss of symptom control can be unpleasant or
inconvenient for a patient, it is not considered to be an
adverse event of equivalent importance to those listed in
Table 6.
A statistical analysis was undertaken using Fisher’s
exact test. Patients who were re-started on their original
medicine were excluded from the analysis. Therefore, the
following data was entered in Fisher’s exact test: 179
accepted recommendations with no adverse outcomes; 226
rejected recommendations with 22 adverse outcomes. This
study found that the risk of having an adverse outcome was
significantly reduced when the pharmacist’s recommenda-
tion to stop or amend a high-risk medicine was followed
compared with continuing a high-risk medicine unchanged
(p\ 0.001).
4 Discussion
The aim of this study was to identify the high-risk
medicines for which a targeted medication review is most
beneficial. Six high-risk medicine groups were identified,
and therefore we recommend that regular review of these
six groups would reduce patient harm. The six medicine
groups are listed in Table 8; we have included a suggested
action, although such actions are at the discretion of the
prescriber because individual patient factors should also be
considered.
This study also set out to determine if targeted medi-
cation reviews can be safely undertaken by a pharmacist.
We have demonstrated that targeted medication reviews of
high-risk medicines conducted by a pharmacist are both
safe and effective. When the pharmacist’s recommenda-
tions were accepted, no adverse events were observed. In
Table 3 Number of pharmacist























1 71 6030 1.18 25.35 5
2 68 5721 1.19 66.18 4
3 14 512 2.73 28.57 2
4 32 2855 1.12 62.50 1
5 17 1248 1.36 58.82 0
6 62 7623 0.81 58.06 2
7 56 2275 2.46 19.64 5
8 17 805 2.11 76.47 1
9 30 2479 1.21 53.33 0
10 0 304 0.00
11 21 2035 1.03 47.62 1
12 17 1209 1.41 35.29 0
13 0 636 0.00
14 0 532 0.00
15 15 2490 0.60 60.00 1
16 20 1645 1.22 80.00 0
Table 4 Summary of the outcomes of 440 recommendations made by pharmacist for high-risk medicines to be stopped or amended
Initial review After 1 year
214 recommendations accepted by GP 128 medicines stopped 76 % remained stopped with no adverse consequences
12 % original medicine re-started
12 % safer medicine re-started
86 medicines amended 69 % remained amended with no adverse consequences
22 % original medicine re-started
9 % safer medicine re-started
226 recommendations rejected by GP 66 % medicines continued with no adverse events
24 % later action taken to reduce risk of an adverse event
10 % an adverse event occurred
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contrast, when the pharmacist’s recommendations were
rejected, 22 preventable adverse events including three
hospital admissions occurred. It is also likely that the
pharmacist’s recommendations triggered later actions by
GPs: in the group in which the pharmacist’s recommen-
dation was initially rejected, the GP implemented the
action at a later date in around 20 % of cases.
These findings support previous research which has
described the value of pharmacist-conducted medication
review [11, 12]. It also adds to the evidence base of pri-
mary care-based pharmacist-led medication reviews in
reducing hospital admissions and drug-related morbidity,
something called for by a previous systematic review [13].
Delivering high-quality pharmaceutical care is central to
pharmacy strategy in Scotland [19]. It is hoped that as
pharmaceutical care services develop, pharmacists in all
settings will consider targeting medication reviews to the
high-risk medicine groups identified in this study.
Table 5 Details of all 440 recommendations made by pharmacist for high-risk medicines to be stopped or amended









Aged[60 years plus anticholinergic 9 5 60.9 9 39.1
Aged[60 years plus antihypertensive and diuretic 2 0 28.6 5 71.4
Aged[60 years plus antipsychotic 4 1 45.5 6 54.5
Aged[60 years plus antipsychotic and hypnotic 1 0 33.3 2 66.7
Aged[60 years plus antipsychotic and tricyclic
antidepressant and anticholinergic
0 0 0.0 1 100.0
Aged[60 years plus antipsychotic and benzodiazepine 0 0 0.0 1 100.0
Aged[60 years plus benzodiazepine and hypnotic 0 2 20.0 8 80.0
Aged[60 years plus benzodiazepine and tricyclic
antidepressant
0 0 0.0 3 100.0
Aged[60 years plus benzodiazepine 1 1 11.8 15 88.2
Aged[60 years plus digoxin 0 8 57.1 6 42.9
Aged[60 years plus diuretic and other antihypertensives 0 2 33.3 4 66.7
Aged[60 years plus hypnotic 4 18 43.1 29 56.9
Aged[60 years plus hypnotic and sedating antihistamine 0 0 0.0 2 100.0
Aged[60 years plus hypnotic and tricyclic antidepressant 1 1 40.0 3 60.0
Aged[60 years plus sedating antihistamine 1 0 33.3 2 66.7
Aged[60 years plus tricyclic antidepressant 11 16 43.5 35 56.5
Aged[60 years plus tricyclic antidepressant and
benzodiazepine
0 0 0.0 2 100.0
Aged[60 years plus tricyclic antidepressant and sedating
antihistamine
1 0 33.3 2 66.7
Heart failure plus glitazone 1 0 100.0 0 0.0
Heart failure plus NSAID 1 0 100.0 0 0.0
Heart failure plus tricyclic antidepressant 5 1 60.0 4 40.0
Triple whammy combination (ACE/
ARB ? NSAID ? diuretic)
55 5 56.1 47 43.9
NSAID plus aged[75 years and no gastro-protection 3 15 75.0 6 25.0
NSAID plus aspirin 1 0 100.0 0 0.0
NSAID plus eGFR\60 mL/min 11 0 42.3 15 57.7
NSAID plus heart failure 2 1 60.0 2 40.0
NSAID plus warfarin 2 0 33.3 4 66.7
Warfarin plus another antiplatelet 10 1 68.8 5 31.3
Warfarin plus macrolide 0 1 100.0 0 0.0
Other 2 8 55.6 8 44.4
Total 128 86 48.6 226 51.4
ACE inhibitor angiotensin converting enzyme inhibitor, ARB angiotensin-II receptor blocker, eGFR estimated glomerular filtration rate, NSAID
non-steroidal anti-inflammatory drug, PPI proton pump inhibitor
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However, such medication reviews need not be restricted to
one profession. Medication review is a core component of
the Quality and Outcomes Framework within the general
medical services contract [20], so GPs may find it useful to
target the high-risk medicine groups identified in this study.
Informal feedback from GPs during the study revealed
that historically not all GPs in the practices included in the
study took a holistic view to medication review. One GP
commented: ‘‘I didn’t really see the value of this project
until a triple whammy combination was pointed out to me.
I realised I had never looked at the persons’ medicines
holistically before so hadn’t considered the risk she was
at’’. Therefore, this study has already helped to inform
better medication review among participating GP practices.
A weakness of our study is that outcomes were only
reviewed after 1 year: it is unlikely that all outcomes would
be observed within 1 year, and therefore a longer follow-up
period would be useful. Therefore, we plan to carry out
further research on the 440 recommendations in our cohort
after 5 years.





Age[60 ? TCA Stop/reduce TCA Fall. Medication considered to be a factor Yes
Age[60 ? TCA Stop/reduce TCA Fall. Medication considered to be a factor Yes
Warfarin ? antiplatelet Review need for
combination
Gastric ulcer Yes
Age[60 ? TCA Stop/reduce TCA Confusion attributed to TCA Yes
Triple whammy Stop NSAID High INR attributed to NSAID Yes
Age[60 ? benzodiazepine Stop/reduce
benzodiazepine
Day-time drowsiness and headache
attributed to benzodiazepine
Yes
Age[60 ? hypnotic Stop/reduce hypnotic Road traffic accident due to next-day
drowsiness
Yes
Age[60 ? TCA Stop/reduce TCA Fall attributed to TCA. Hospital
admission
Yes
Triple whammy Stop NSAID Reflux due to NSAID Yes
Age[60 ? multiple antihypertensives Consider reduction of
antihypertensives
Decreased renal function requiring
antihypertensive to be stopped
Yes
Age[60 ? multiple antihypertensives Consider reduction of
antihypertensives
Low blood pressure Yes
Age[60 ? multiple antihypertensives Consider reduction of
antihypertensives
Falls and low blood pressure Yes
Age[60 ? antipsychotic ? TCA ? anticholinergics Stop/reduce TCA Fall. Medication considered to be a factor.
Hospital admission
Yes
Age[75 ? PPI no gastroprotection Start PPI Gastrointestinal bleeding requiring
NSAID to be stopped
Yes
Age[60 ? hypnotic ?TCA Stop/reduce hypnotic and
TCA
Fall. Medication considered to be a factor Yes
Age[60 ? antipsychotic Stop/reduce
antipsychotic
Fall. Medication considered to be a factor Yes
Triple whammy and NSAID in reduced renal function Stop NSAID Gastrointestinal side effects requiring
NSAID to be stopped
Yes
Age[60 ? benzodiazepine ? TCA Stop/reduce
benzodiazepine and
TCA
Falls and confusion attributed to
medication
Yes
Age[60 ? hypnotic Stop/reduce hypnotic Drowsiness Yes
Age[60 ? hypnotic Stop/reduce hypnotic Fall. Medication considered to be a factor.
Hospital admission
Yes
Age[60 ? multiple antihypertensives Consider reduction of
antihypertensives
Fall. Medication considered to be a factor Yes
Age[60 ? multiple antihypertensives Consider reduction of
antihypertensives
Oedema due to amlodipine requiring dose
reduction
No
INR international normalised ratio, NSAID non-steroidal anti-inflammatory drug, PPI proton pump inhibitor, TCA tricyclic antidepressant
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A further weakness of our study was that we did not control
for potential confounding factors in our statistical analysis.
Our study was a prospective study which took a real-life
approach. There were many potential confounding factors in
the decision to accept or reject the pharmacist’s recommen-
dations. The biggest confounder was the variability between
GPs at the 16 practices in their clinical judgement on deciding
whether or not to accept the pharmacist’s recommendation
(see Table 3). Some GPs were less engaged in the study than
others, perhaps due to time pressures or willingness to accept
advice from a pharmacist. Controlling for this confounder was
not possible without limiting the study to one GP practice,
which would have resulted in the population size being too
small. Further confounders include the patient being in an
unstable condition (e.g. due to co-morbidity or life circum-
stances) so it being an inappropriate time to implement a
change to medicines, GP knowledge of a patient’s past
acceptance of medicine changes, and GP knowledge of a
patient’s ability to cope with a change to medicines. Within
our real-life study population, it was impossible to identify all
the potential confounders. Therefore, we decided not to
control for confounders. A future area for research would be to
design a revised version of this study that did control for these
confounders.
We do not believe there was any bias in the pharmacist’s
reviews and recommendations. Each recommendation sta-
ted the evidence base upon which it was made, therefore
reducing the risk of bias.
5 Conclusion
This study demonstrated that medication reviews for high-
risk medicines are safe and effective, and that pharmacists
are effective at delivering medication reviews. It identified
six high-risk medicines that could form the basis of targeted
medication reviews in order to reduce iatrogenic disease.
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Table 7 List of medicines
which were later re-started
following being stopped or
amended in line with the
pharmacist’s advice
High-risk medicine combination Number of times original medicine re-started
Aged[60 years plus anticholinergic 3
Aged[60 years plus antihypertensive and diuretic 3
Aged[60 years plus antipsychotic 1
Aged[60 years plus antipsychotic and hypnotic 1 (hypnotic only)
Aged[60 years plus hypnotic 9
Aged[60 years plus tricyclic antidepressant 7
Heart failure plus tricyclic antidepressant 1
NSAID plus ACE inhibitor/ARB and diuretic 7
NSAID plus eGFR\60 mL/min 2
NSAID plus heart failure 1
Total 35
ACE inhibitor angiotensin converting enzyme inhibitor ARB angiotensin-II receptor blocker, eGFR esti-
mated glomerular filtration rate, NSAID non-steroidal anti-inflammatory drug
Table 8 Six key high-risk medicines to target in regular medication
reviews
High-risk medicine Suggested action
Triple whammy combination (NSAID,
diuretic, ACE inhibitor)
Stop NSAID
NSAID ? reduced renal function Stop NSAID
NSAID ? age[75 ? no PPI Stop NSAID or add PPI
Hypnotic/benzodiazepine ? age[60 Reduce or stop hypnotic/
benzodiazepine
Tricyclic antidepressant ? age[60 Reduce or stop tricyclic
antidepressant
Antipsychotic ? age[60 Reduce or stop
antipsychotic
NSAID non-steroidal anti-inflammatory drug, ACE inhibitor angio-
tensin converting enzyme inhibitor, PPI proton pump inhibitor
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Appendix 1: High-risk medicines pharmacist
reporting tool
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